AR098818A1 - Derivados de oxindol, preparación de los mismos y uso terapéutico de los mismos - Google Patents

Derivados de oxindol, preparación de los mismos y uso terapéutico de los mismos

Info

Publication number
AR098818A1
AR098818A1 ARP140104745A ARP140104745A AR098818A1 AR 098818 A1 AR098818 A1 AR 098818A1 AR P140104745 A ARP140104745 A AR P140104745A AR P140104745 A ARP140104745 A AR P140104745A AR 098818 A1 AR098818 A1 AR 098818A1
Authority
AR
Argentina
Prior art keywords
group
substituted
unsubstituted
alkyl group
alkyl
Prior art date
Application number
ARP140104745A
Other languages
English (en)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR098818A1 publication Critical patent/AR098818A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente solicitud se refiere a compuestos y procesos para la preparación de estos y usos terapéuticos de los mismos. Reivindicación 1: Un compuesto que corresponde a la fórmula (1) en donde R¹ representa: un grupo arilo C₆₋₁₀, sin sustituir o sustituido con uno o más sustituyentes seleccionados entre un átomo de halógeno, un grupo -ORᵃ, en donde Rᵃ representa un átomo de hidrógeno, un grupo alquilo C₁₋₃ o un grupo -CF₃, un grupo alquilo C₁₋₃, sin sustituir o sustituido con uno o más átomos de halógeno, un grupo carboxilo, un grupo ciano, un grupo heterocicloalquilo C₃₋₆, sin sustituir o sustituido con uno o más grupos alquilo C₁₋₃; un grupo heteroarilo C₂₋₁₀, sin sustituir o sustituido con uno o más sustituyentes seleccionados entre un átomo de halógeno, un grupo alquilo C₁₋₄, un grupo cicloalquilo C₃₋₆, un grupo -ORᵉ, en donde Rᵉ representa un átomo de hidrógeno o un grupo alquilo C₁₋₄, estando dicho grupo alquilo C₁₋₄ sin sustituir o sustituido con uno o más grupos alcoxi C₁₋₄ o heterocicloalquilo, un grupo -NRᶠRᶠ, en donde Rᶠ y Rᶠ, independientemente, idénticos o diferentes, representan un grupo alquilo C₁₋₃; R² representa: un grupo arilo C₆₋₁₀, sin sustituir o sustituido con uno o más sustituyentes seleccionados entre: un átomo de halógeno, un grupo ciano, un grupo de fórmula (2), un grupo de fórmula (3), un grupo, un grupo alquilo C₁₋₃ sin sustituir o sustituido con uno o más sustituyentes seleccionados entre un átomo de halógeno, un grupo hidroxilo y un grupo alquenilo C₁₋₄, un grupo cicloalquilo C₃₋₆, sin sustituir o sustituido con un grupo hidroxialquilo C₁₋₃, un grupo hidroxilo o un grupo alcoxi C₁₋₄, un grupo -ORᵇ, en donde Rᵇ representa un átomo de hidrógeno, un grupo -CF₃, un grupo cicloalquilo C₃₋₆, sin sustituir o sustituido con un grupo hidroxilo, un grupo heterocicloalquilo C₃₋₆, estando dicho grupo heterocicloalquilo C₃₋₆ sin sustituir o sustituido con un grupo alquilo C₁₋₃, o un grupo alquilo C₁₋₃, estando dicho grupo alquilo C₁₋₃ sin sustituir o sustituido con uno o más: grupo hidroxilo, grupo alcoxi C₁₋₄, grupo heteroarilo C₂₋₁₀, grupo acetamido, grupo dialquil C₁₋₃-amino, grupo cicloalquilo C₃₋₆, estando dicho grupo cicloalquilo C₃₋₆ sin sustituir o sustituido con uno o más grupos hidroxilo, o grupo heterocicloalquilo C₃₋₆, estando dicho grupo heterocicloalquilo C₃₋₆ sin sustituir o sustituido con un grupo alquilo C₁₋₃; un grupo heterocicloalquilo C₃₋₆ sin sustituir o sustituido con uno o más de átomo de halógeno, grupo alquilo C₁₋₃, grupo hidroxilo, grupo hidroxialquilo C₁₋₃, grupo alcoxi C₁₋₄ o grupo fluoroalquilo C₁₋₄, un grupo arilo C₆₋₁₀, sin sustituir o sustituido con uno o más grupos -ORᶜ, en donde Rᶜ representa un átomo de hidrógeno o un grupo alquilo C₁₋₃, un grupo heteroarilo C₂₋₁₀, sin sustituir o sustituido con uno o más grupos -NH₂, un grupo -NRᵈRᵈ, en donde Rᵈ y Rᵈ, independientemente, idénticos o diferentes, representan un átomo de hidrógeno, un grupo alquilo C₁₋₃, un grupo hidroxi-alquilo C₁₋₄ o un grupo cicloalquilo C₃₋₆, o un grupo heteroarilo C₂₋₁₀, sin sustituir o sustituido con uno o más sustituyentes seleccionados entre: un grupo alquilo C₁₋₃, un grupo cicloalquilo C₃₋₆, sin sustituir o sustituido con un grupo hidroxi-alquilo C₁₋₃, un grupo -NRᵍRᵍ, en donde Rᵍ y Rᵍ, independientemente, idénticos o diferentes, representan un grupo alquilo C₁₋₃; R³ represente: un átomo de halógeno, un grupo alquilo C₁₋₃; R⁴ representa: un átomo de halógeno, un átomo de hidrógeno; en la forma de la base, enantiómeros, diastereómeros o de una sal de adición con un ácido o con una base. Reivindicación 18: Compuestos de fórmula (4), (5), (6), (7) y (8) en donde R¹, R², R³ son como se han definido en la reivindicación 1 y R representa un grupo alquilo, PG y PG² representan grupos protectores, R² representa un grupo arilo sustituido con un grupo arilo.
ARP140104745A 2013-12-19 2014-12-18 Derivados de oxindol, preparación de los mismos y uso terapéutico de los mismos AR098818A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13306793.4A EP2886541A1 (en) 2013-12-19 2013-12-19 Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases

Publications (1)

Publication Number Publication Date
AR098818A1 true AR098818A1 (es) 2016-06-15

Family

ID=49989457

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104745A AR098818A1 (es) 2013-12-19 2014-12-18 Derivados de oxindol, preparación de los mismos y uso terapéutico de los mismos

Country Status (13)

Country Link
US (1) US10077237B2 (es)
EP (2) EP2886541A1 (es)
JP (1) JP6436999B2 (es)
KR (1) KR20160093073A (es)
CN (1) CN106029656B (es)
AR (1) AR098818A1 (es)
AU (1) AU2014368476B2 (es)
CA (1) CA2932343A1 (es)
IL (1) IL245738A0 (es)
MX (1) MX2016007989A (es)
RU (1) RU2016129018A (es)
TW (1) TW201609644A (es)
WO (1) WO2015091937A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2646993B1 (es) * 2016-06-17 2018-09-25 Consejo Superior De Investigaciones Científicas (Csic) Derivados de indolin-2-ona y su uso terapéutico
CN110818611B (zh) * 2018-08-13 2023-01-24 中国科学院上海药物研究所 一类吲哚酮类化合物、其制备方法、药物组合物和用途
WO2020061231A1 (en) * 2018-09-18 2020-03-26 1Globe Biomedical Co., Ltd. Treatment for obesity
RU2734495C1 (ru) * 2019-09-13 2020-10-19 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ лечения сахарного диабета
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
KR102566028B1 (ko) * 2021-08-10 2023-08-10 계명대학교 산학협력단 신규한 다중 단백질 키나아제 억제제
WO2023196640A1 (en) 2022-04-08 2023-10-12 Bioverativ Therapeutics Inc. Oxindole derivatives as ampk activators for use in the treatment of rare blood disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3767653A (en) * 1971-06-28 1973-10-23 Squibb & Sons Inc Thiazines
US3984405A (en) 1971-06-28 1976-10-05 E. R. Squibb & Sons, Inc. Anti-inflammatory agents
HU163625B (es) * 1971-06-28 1973-09-27
US3923996A (en) 1972-07-31 1975-12-02 Sandoz Ag 3-Substituted-oxindoles in compositions and methods of treating obesity
NL7310394A (es) * 1972-07-31 1974-02-04
US4853409A (en) * 1988-04-13 1989-08-01 Pfizer Inc. 3-substituted-2-oxindole-1-carboxamides for suppressing T-cell function
HU215112B (hu) * 1989-01-10 1998-12-28 Pfizer Inc. Eljárás gyulladáscsökkentő 1-heteroaril-3-acil-2-oxindol-származékok előállítására
US5006547A (en) * 1990-03-19 1991-04-09 Pfizer Inc. Tenidap as an inhibitor of the release of elastase by neutrophils
CN102666485A (zh) * 2009-09-21 2012-09-12 霍夫曼-拉罗奇有限公司 烯烃羟吲哚衍生物及其用于治疗肥胖症，糖尿病和高脂血症的应用
WO2011032320A1 (en) 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives

Also Published As

Publication number Publication date
JP2016540784A (ja) 2016-12-28
JP6436999B2 (ja) 2018-12-12
CN106029656B (zh) 2019-07-26
US10077237B2 (en) 2018-09-18
CN106029656A (zh) 2016-10-12
EP2886541A1 (en) 2015-06-24
IL245738A0 (en) 2016-08-02
AU2014368476A1 (en) 2016-06-30
TW201609644A (zh) 2016-03-16
MX2016007989A (es) 2016-09-13
CA2932343A1 (en) 2015-06-25
RU2016129018A (ru) 2018-01-25
EP3083611B1 (en) 2019-02-13
WO2015091937A1 (en) 2015-06-25
US20160311770A1 (en) 2016-10-27
EP3083611A1 (en) 2016-10-26
KR20160093073A (ko) 2016-08-05
AU2014368476B2 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
AR098818A1 (es) Derivados de oxindol, preparación de los mismos y uso terapéutico de los mismos
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR079226A1 (es) Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer
AR100137A1 (es) Compuestos 4-amino-imidazoquinolina
AR088000A1 (es) Derivados de pirazolquinolinona, su preparacion y su uso terapeutico
AR093515A1 (es) Triazolopirazinas
CU20170164A7 (es) Compuestos n-tieno (2,3-d)pirimidinil-d-fenilalanina, método para preparar los mismos y composiciones farmacéuticas que los contienen
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR094342A1 (es) Derivados de ácido borónico útiles como agentes antimicrobianos
AR098912A1 (es) Inhibidores de syk
AR091156A1 (es) Nucleosidos de espirooxetano de uracilo
AR094346A1 (es) Derivados de azaindol como inhibidores de las proteína quinasas
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR090328A1 (es) Pirrolidina-2-carboxamidas sustituidas
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
ES2626801T3 (es) Compuestos de triazolopiridina como inhibidores de pde10a
AR109735A1 (es) Método para la síntesis de derivado de 3-fenil-2,3,4,8,9,10-hexahidropirano[2,3-f]cromeno e isómero óptico del mismo
AR101479A1 (es) Derivados de 6-alquinil-piridina
AR100776A1 (es) Compuestos herbicidas
AR097253A1 (es) Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida
PE20161240A1 (es) Agentes anticancerosos y sus preparaciones

Legal Events

Date Code Title Description
FB Suspension of granting procedure